NewAmsterdam Pharma (NAMS) Total Non-Current Liabilities (2021 - 2024)

NewAmsterdam Pharma has disclosed Total Non-Current Liabilities across 4 years of filings, most recently posting $41.5 million for Q3 2024.

• Total Non-Current Liabilities for Q3 2024 came in at $41.5 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $41.5 million (changed N/A YoY), and the FY2023 annual result was $50.9 million, up 330.18% from the prior year.
• Total Non-Current Liabilities came in at $41.5 million for Q3 2024 at NewAmsterdam Pharma, down from $45.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $60.2 million in Q1 2024 to a low of $126980.8 in Q4 2021.
• The 4-year median for Total Non-Current Liabilities is $41.5 million (2024), against an average of $31.7 million.
• Across the five-year window, Total Non-Current Liabilities jumped 9221.01% in 2022 and jumped 301.11% in 2024, its largest moves.
• NewAmsterdam Pharma's Total Non-Current Liabilities stood at $126980.8 in 2021, then surged by 9221.01% to $11.8 million in 2022, then soared by 330.18% to $50.9 million in 2023, then declined by 18.45% to $41.5 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $41.5 million (Q3 2024), $45.9 million (Q2 2024), and $60.2 million (Q1 2024), per Business Quant data.